Context Therapeutics Inc. (NASDAQ: CNTX) stock is up about 12% after the biopharmaceutical Company announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).<\/p>\n\n\n\n
\u201cThe data from the ONAWA trial signal the potential of ONA-XR to help inhibit tumor proliferation and shift tumors to a more endocrine treatment-sensitive phenotype during treatment prior to surgery in postmenopausal women with operable breast cancer and improve overall prognosis for these patients. These results support further evaluation of ONA-XR in the treatment of early breast cancer.\u201d<\/p>co-principal investigator Meritxell Bellet, M.D., Ph.D., medical oncologist at Vall d’Hebron University Hospital in Barcelona and an executive board member of SOLTI<\/cite><\/blockquote>\n\n\n\nThe Phase 0 open-label, single-arm, multicenter ONAWA (SOLTI-1802) trial conducted by Spanish cancer research group SOLTI, enrolled 10 patients with ER+\/PR+\/HER2- negative tumors and levels of the cell proliferation marker “Ki67” above 10% to evaluate ONA-XR by the rate of Complete Cell Cycle Arrest (CCCR) determined by Ki-67 (\u22642.7%) when administered for three weeks prior to surgery (Abstract #511).<\/p>\n\n\n\n
\u201cONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers. This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers. We look forward to data updates from three other ONA-XR trials in 2022.\u201d<\/p>Martin Lehr, CEO of Context Therapeutics<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Context Therapeutics Inc. (NASDAQ: CNTX) stock is up about 12% after the biopharmaceutical Company announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021… View Article<\/a>","protected":false},"author":3,"featured_media":17469,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nContext Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"Context Therapeutics Inc. (NASDAQ: CNTX) stock is up about 12% after the biopharmaceutical Company announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-10T17:15:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-10T17:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/09\/CancerResearch.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer\",\"datePublished\":\"2021-12-10T17:15:04+00:00\",\"dateModified\":\"2021-12-10T17:15:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\",\"url\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\",\"name\":\"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2021-12-10T17:15:04+00:00\",\"dateModified\":\"2021-12-10T17:15:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News & Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth","og_description":"Context Therapeutics Inc. (NASDAQ: CNTX) stock is up about 12% after the biopharmaceutical Company announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021... View Article","og_url":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2021-12-10T17:15:04+00:00","article_modified_time":"2021-12-10T17:15:06+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/09\/CancerResearch.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer","datePublished":"2021-12-10T17:15:04+00:00","dateModified":"2021-12-10T17:15:06+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/","url":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/","name":"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2021-12-10T17:15:04+00:00","dateModified":"2021-12-10T17:15:06+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/context-therapeutics-shares-rise-after-positive-data-from-ona-xr-in-early-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News & Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18117"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=18117"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18117\/revisions"}],"predecessor-version":[{"id":18118,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18117\/revisions\/18118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/17469"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=18117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=18117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=18117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}